Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

Definium Therapeutics has raised $700 million by increasing its public offering, signaling strong investor confidence in its innovative therapeutics for psychiatric and neurological disorders. This sizable funding could accelerate its drug development and bring new treatments to market faster. The move is significant as it underscores the growing market interest in biopharmaceutical innovations targeting mental health, potentially reshaping the industry landscape.